CN108578606A - Treat the Chinese medicine preparation of rheumatoid arthritis - Google Patents
Treat the Chinese medicine preparation of rheumatoid arthritis Download PDFInfo
- Publication number
- CN108578606A CN108578606A CN201810865992.2A CN201810865992A CN108578606A CN 108578606 A CN108578606 A CN 108578606A CN 201810865992 A CN201810865992 A CN 201810865992A CN 108578606 A CN108578606 A CN 108578606A
- Authority
- CN
- China
- Prior art keywords
- group
- radix
- present
- rheumatoid arthritis
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
- A61K36/515—Gentiana
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a kind of Chinese medicine preparation for treating rheumatoid arthritis, is for Chinese traditional medicine water extract for oral administration, the Chinese medicine and mass ratio are as follows:Radix Astragali 35, cassia twig 15, stir-baked RADIX PAEONIAE ALBA 25, Radix Aconiti Lateralis Preparata 10, Radix Angelicae Sinensis 15, coix seed 25, windproof 15, bark of ash 15, Rhizoma Et Radix Notopterygii 10, Rhizoma Chuanxiong 10, rhizoma atractylodis 15, Radix Glycyrrhizae 15.The present invention treats Small side effects caused by rheumatoid arthritis, by being detected to RF, TNF α, IL 6,10 contents of IL in the mouse Articular swelling and serum after treatment, the results showed that the effect of present invention is to rheumatoid arthritis is better than the prior art.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation, especially a kind of Small side effects, eutherapeutic treatment rheumatoid arthritis
Chinese medicine preparation.
Background technology
Rheumatoid arthritis(RA)It is a kind of general immunity arthritis, is one of the chronic disease for seriously threatening health.
It is mainly characterized by chronic, symmetry, progressive and invasion, the arthroncus deformation being embodied in caused by arthrosynovitis
And osteoclasia, notably disable.The cause of disease and pathogenesis of RA not yet illustrates, and inflammatory change is its typical pathological change, is immunized
The progress that system and synovial tissue's cell and its cell factor of secretion aggravate disease.In recent years, domestic and foreign scholars are according to evidence-based
Medical evidence proposes that the therapeutic purpose of RA is so that patient is reached remission state as early as possible and remain steady in a long-term.Clinically RA is normal
The medicine seen is divided into three categories:Non-steroid anti-inflammatory drug(NSAIDS), glucocorticoid(GCS)And improve the wind resistance of the state of an illness
Wet medicine(DMARDS).Methotrexate (MTX)(MTX)For antirheumatic drug(DMARDS)Choice drug,
But the constitutional symptoms such as weak, fever can be brought, epigastric discomfort is lost the appetite, and oral cavity ulceration, hemorrhage of digestive tract etc. disappears
Change road symptom, the adverse reactions such as three system of haemocyte reduction.Said medicine is often because curative effect does not comply with one's wishes or toxic side effect is larger and difficult
To promote or be used for a long time.RA belongs to the scope of " bi Zheng ", Huangqi Guizhi Wuwu Tang in Chinese medicine(Radix Astragali, cassia twig, Chinese herbaceous peony, life
Ginger and jujube)Or Guizhi-Shoyao-Zhimu Decoction(Cassia twig, Chinese herbaceous peony, Radix Glycyrrhizae, Chinese ephedra, ginger, Rhizoma Atractylodis Macrocephalae, rhizoma anemarrhenae, windproof and Radix Aconiti Lateralis Preparata)For
More famous compound, Small side effects, but therapeutic effect is not very ideal.
Invention content
The present invention is to provide a kind of Small side effects, good effect to solve the above-mentioned technical problem present in the prior art
Treatment rheumatoid arthritis Chinese medicine preparation.
Technical solution of the invention is:A kind of Chinese medicine preparation for treating rheumatoid arthritis, it is characterised in that be to use
In Chinese traditional medicine water extract for oral administration, the Chinese medicine and mass ratio are as follows:Radix Astragali 35, cassia twig 15, stir-baked RADIX PAEONIAE ALBA 25, Radix Aconiti Lateralis Preparata 10, Radix Angelicae Sinensis
15, coix seed 25, windproof 15, bark of ash 15, Rhizoma Et Radix Notopterygii 10, Rhizoma Chuanxiong 10, rhizoma atractylodis 15, Radix Glycyrrhizae 15.
Herbal toxic effect used in the present invention is small, by RF, TNF in the mouse Articular swelling and serum after treatment
α, IL-6, IL-10 content are detected, the results showed that the effect of present invention is to rheumatoid arthritis is better than the prior art.
Specific implementation mode
The Chinese medicine preparation of the treatment rheumatoid arthritis of the present invention, be for Chinese traditional medicine water extract for oral administration, the Chinese medicine and
Quality is as follows:Radix Astragali 35g, cassia twig 15g, stir-baked RADIX PAEONIAE ALBA 25g, Radix Aconiti Lateralis Preparata 10g, Radix Angelicae Sinensis 15g, coix seed 25g, windproof 15g, bark of ash
15g, Rhizoma Et Radix Notopterygii 10g, Rhizoma Chuanxiong 10g, rhizoma atractylodis 15g, Radix Glycyrrhizae 15g.
Preparation method is first by the independent decocting 30min of Radix Aconiti Lateralis Preparata, remaining Chinese medicine adds 10 times of distilled waters to impregnate 30min, pours into
It in Radix Aconiti Lateralis Preparata decocting liquid, boils by intense fire, is adjusted to be cooked by slow fire 2h, poured into container after concoction cooling.Add 8 times into the dregs of a decoction again
Distilled water boils by intense fire, is adjusted to be cooked by slow fire 2h, then concoction is poured into container, i.e., gained concoction will mix twice.Later will
The extracting solution that proportion is 4g/mL is made in being concentrated on Rotary Evaporators in concoction in container.
Experiment:
1. grouping
80 200 ± 20g SD rats adaptable feds 1 week, are randomly divided into 8 groups, blank group 10, model group 10, positive drug
Group 10, low dose group of the embodiment of the present invention 10, middle dosage of the embodiment of the present invention 10, high dose group of the embodiment of the present invention 10
Only, Huangqi Guizhi Wuwu Tang group 10, Guizhi-Shoyao-Zhimu Decoction group 10.
It is prepared by rat rheumatoid arthritis model
With reference to the modeling method of Freund, 10% chloraldurate of SD rats(0.3ml/100g)After abdominal cavity holonarcosis(Without blink
It is painless to pinch foot for reaction), 75% alcohol disinfecting of right toes, in addition to blank group rat, the subcutaneous multiple spot note of remaining group rat
Complete Freund's adjuvant 0.2mL is penetrated, injection 0.1mL complete Freund's adjuvant booster immunizations are primary after 1 week, and arthritis is carried out after two weeks
Scoring is 4 points;Blank group rat injects normal saline.
3. prepared by medicament
Huangqi Guizhi Wuwu Tang:By Radix Astragali(15g), cassia twig(12g), Chinese herbaceous peony(12g), ginger(25g), 4 pieces of ratio structures of jujube
At.The same embodiment of the present invention of extraction process, is made 4g/mL extracting solutions.
Guizhi-Shoyao-Zhimu Decoction:By cassia twig(12g), Chinese herbaceous peony(9g), Radix Glycyrrhizae(6g), Chinese ephedra(12g), ginger(15g), Rhizoma Atractylodis Macrocephalae
(15g), rhizoma anemarrhenae(12g), it is windproof(12g), Radix Aconiti Lateralis Preparata(10g)Composition of proportions.The same embodiment of the present invention of extraction process, is made 4g/
ML extracting solutions.
4. administration
Normal group and model group give the physiological saline of therapeutic dose after 24 h of modeling;Positive drug group methotrexate (MTX) physiology
Brine configures, ultrasonic dissolution, and administration concentration is 0.1 mg/mL, and dosage is 1 mg/kg;The embodiment of the present invention is basic, normal, high
Dosage group gives the embodiment of the present invention, and dosage is respectively 10 g/kg, 20 g/kg, 40 g/kg;Huangqi Guizhi Wuwu Tang group
Dosage is 40 g/kg;Guizhi-Shoyao-Zhimu Decoction group dosage is 40g/kg.Every group is administered once a day, successive administration 5
Week.
5. detection
Vernier caliper measurement Articular swelling is used after modeling weekly, calculate and records Articular swelling increase percentage.It calculates public
Formula be Articular swelling increase percentage=(Minute point joint diameter-initial diameter)/ initial diameter × 100%.In last
Rat blood serum is taken after administration, and RF, TNF α, IL-6, IL-10, IL-1 β content in serum are detected using enzyme-linked immunization,
Specific detecting step, method are operated by kit specification.
6. statistical method
All data are calculated using SPSS16.0 softwares, measurement data mean ± standard deviationIt indicates, between group
Compare and uses independent sampletIt examines,p≤ 0.05 has statistical significance.
7. result
7.1 Articular swelling results such as table 1-1, table 1-2.
Table 1-1
Table 1-2
*P<0.05, **P<0.01, compared with model group;#P<0.05, ##P<0.01, compared with blank group.
As a result it shows:Each point in time, blank control group and the significant difference of model group illustrate modeling success.From
Start within three weeks, positive drug group and the significant difference of model group, illustrates that methotrexate (MTX) has therapeutic effect.From 4th week, this
Inventive embodiments administration group, than significant difference, illustrates that the embodiment of the present invention there is treatment to make rheumatoid with model group
With.From 4th week, Huangqi Guizhi Wuwu Tang group and Guizhi-Shoyao-Zhimu Decoction group and model group ratio are statistically significant, illustrate Huang
Five object soup of stilbene cassia twig and Guizhi-Shoyao-Zhimu Decoction have therapeutic effect to rheumatoid arthritis, while can be seen that the present invention is implemented
Example curative effect is better than positive drug group, Huangqi Guizhi Wuwu Tang group and Guizhi-Shoyao-Zhimu Decoction group.
RF, TNF α, IL-6, IL-10 content detection result such as table 2-1, table 2-2 in 7.2 serum
Table 2-1
Table 2-2
*P<0.05, **P<0.01, compared with model group;#P<0.05, ##P<0.01, compared with blank group.
The result shows that:
① RF:Blank group and model group ratio are statistically significant, prompt modeling success;Positive drug group and model group, blank group ratio
It is statistically significant, make RF close to normal level, prompts methotrexate (MTX) that there is therapeutic effect.Low dose group of the embodiment of the present invention
It is statistically significant with model group, positive drug group ratio, it prompts low dosage of the embodiment of the present invention to have and alleviates rheumatoid arthritis
Effect.Middle dose group of the embodiment of the present invention with model group than statistically significant, it is not statistically significant with positive drug group, prompt
Middle dosage of the embodiment of the present invention has therapeutic effect to rheumatoid arthritis.High dose group of the embodiment of the present invention and model group, sun
Property medicine group ratio it is statistically significant, and make RF closer to normal level, prompt high-dose therapy effect of the embodiment of the present invention excellent
In methotrexate (MTX).Huangqi Guizhi Wuwu Tang group and Guizhi-Shoyao-Zhimu Decoction group and model group ratio are statistically significant, prompt Radix Astragali
Five object soup of cassia twig and Guizhi-Shoyao-Zhimu Decoction have therapeutic effect to rheumatoid arthritis, but therapeutic effect is only better than the present invention
Embodiment low dose group is not so good as high dose group of the embodiment of the present invention.
② TNFα:Blank group and model group ratio are statistically significant, prompt modeling success;Positive drug group and model group ratio
Statistically significant, with blank group than not statistically significant, prompt methotrexate (MTX) has fabulous therapeutic effect.The present invention is implemented
Example low dose group and model group, positive drug group ratio are statistically significant, prompt low dosage of the embodiment of the present invention to have and alleviate class
The effect of rheumathritis.Middle dose group of the embodiment of the present invention is with model group, positive drug group than statistically significant, and prompt is originally
Inventive embodiments middle dosage has therapeutic effect to rheumatoid arthritis.High dose group of the embodiment of the present invention and model group, the positive
Medicine group ratio is statistically significant, and makes TNF α close to normal level, and high dose of the embodiment of the present invention is prompted to have therapeutic effect.
Huangqi Guizhi Wuwu Tang group and Guizhi-Shoyao-Zhimu Decoction group and model group ratio are statistically significant, prompt Huangqi Guizhi Wuwu Tang and
Guizhi-Shoyao-Zhimu Decoction has a therapeutic effect to rheumatoid arthritis, but the therapeutic effect and embodiment of the present invention is low, middle dosage
Group effect is suitable, is not so good as high dose group of the embodiment of the present invention.
③ IL-6:Blank group and model group ratio are statistically significant, prompt modeling success;Positive drug group and model group, sky
White group ratio is statistically significant, makes IL-6 close to normal level, methotrexate (MTX) is prompted to have therapeutic effect.The embodiment of the present invention
Low dose group is not statistically significant with model group, and low dosage of the embodiment of the present invention is prompted not have therapeutic effect.The embodiment of the present invention
Middle dose group and model group, positive drug group ratio are statistically significant, prompt middle dosage of the embodiment of the present invention to rheumatoid arthrosis
Inflammation has therapeutic effect, but therapeutic effect unobvious.High dose group of the embodiment of the present invention and model group are statistically significant, with sun
Property medicine group it is not statistically significant, make IL-6 close to normal level, prompt high dose of the embodiment of the present invention that there is treatment rheumatoid to close
Save scorching effect.Huangqi Guizhi Wuwu Tang group and Guizhi-Shoyao-Zhimu Decoction group and model group ratio are statistically significant, prompt Radix Astragali
Five object soup of cassia twig and Guizhi-Shoyao-Zhimu Decoction have therapeutic effect to rheumatoid arthritis, but therapeutic effect and the present invention are implemented
Example middle dose group is suitable, is not so good as high dose group of the embodiment of the present invention.
④ IL-10:Blank group and model group ratio are statistically significant, prompt modeling success;Positive drug group and model group,
Blank group ratio is statistically significant, makes IL-10 close to normal level, methotrexate (MTX) is prompted to have therapeutic effect.The present invention is real
It is statistically significant with model group to apply a low dose group, prompts low dosage of the embodiment of the present invention invalid to rheumatoid arthritis.This
Inventive embodiments middle dose group and model group, positive drug group ratio are statistically significant, prompt middle dosage pair of the embodiment of the present invention
Rheumatoid arthritis has therapeutic effect, but therapeutic effect unobvious.High dose group of the embodiment of the present invention and model group, positive drug
Group ratio is statistically significant, and high dose of the embodiment of the present invention is prompted to have therapeutic effect to rheumatoid arthritis.Radix Astragali cassia twig
Five object soup groups and Guizhi-Shoyao-Zhimu Decoction group and model group ratio are statistically significant, prompt Huangqi Guizhi Wuwu Tang and cassia twig Chinese herbaceous peony
Anemarrhenae Decoction has therapeutic effect to rheumatoid arthritis, but therapeutic effect and middle dose group of the embodiment of the present invention are suitable, are not so good as
High dose group of the embodiment of the present invention.
Claims (1)
1. a kind of Chinese medicine preparation for treating rheumatoid arthritis, it is characterised in that be for Chinese traditional medicine water extract for oral administration, in described
Medicine and mass ratio are as follows:Radix Astragali 35, cassia twig 15, stir-baked RADIX PAEONIAE ALBA 25, Radix Aconiti Lateralis Preparata 10, Radix Angelicae Sinensis 15, coix seed 25, windproof 15, bark of ash 15,
Rhizoma Et Radix Notopterygii 10, Rhizoma Chuanxiong 10, rhizoma atractylodis 15, Radix Glycyrrhizae 15.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810865992.2A CN108578606B (en) | 2018-08-01 | 2018-08-01 | Traditional Chinese medicine preparation for treating rheumatoid arthritis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810865992.2A CN108578606B (en) | 2018-08-01 | 2018-08-01 | Traditional Chinese medicine preparation for treating rheumatoid arthritis |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108578606A true CN108578606A (en) | 2018-09-28 |
CN108578606B CN108578606B (en) | 2021-02-19 |
Family
ID=63619053
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810865992.2A Active CN108578606B (en) | 2018-08-01 | 2018-08-01 | Traditional Chinese medicine preparation for treating rheumatoid arthritis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108578606B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113134064A (en) * | 2021-04-27 | 2021-07-20 | 广东省中医院(广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院) | Composition for preventing rheumatoid arthritis and preparation method and application thereof |
CN115814048A (en) * | 2022-12-09 | 2023-03-21 | 北京马家一绝中医风湿骨病研究院 | Chinese medicine for treating rheumatism and its preparation |
-
2018
- 2018-08-01 CN CN201810865992.2A patent/CN108578606B/en active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113134064A (en) * | 2021-04-27 | 2021-07-20 | 广东省中医院(广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院) | Composition for preventing rheumatoid arthritis and preparation method and application thereof |
CN115814048A (en) * | 2022-12-09 | 2023-03-21 | 北京马家一绝中医风湿骨病研究院 | Chinese medicine for treating rheumatism and its preparation |
Also Published As
Publication number | Publication date |
---|---|
CN108578606B (en) | 2021-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104367911A (en) | Traditional Chinese medicinal composition for treating rheumatic arthritis and rheumatoid arthritis and preparation method thereof | |
CN104353047A (en) | Traditional Chinese medicine for treating nephritis | |
CN104383055A (en) | Drug for treating end-stage liver diseases caused by chronic hepatitis B and preparation method of drug | |
CN102988672A (en) | Traditional Chinese medicine composition for treating irregular menstruation | |
CN103705797B (en) | A kind of medicine for the treatment of renal calculus | |
CN101011544A (en) | Gout rapid recovery pill(capsule) and preparation technique thereof | |
CN101991752A (en) | Traditional Chinese medicine formula for treating gout | |
CN108578606A (en) | Treat the Chinese medicine preparation of rheumatoid arthritis | |
CN113713039A (en) | Traditional Chinese medicine composition for treating membranous nephropathy and application thereof | |
CN103860659A (en) | Traditional Chinese medicine for treating early nephrolith | |
CN104027684A (en) | Traditional Chinese medicinal composition for treating gout and preparation method thereof | |
CN103933513A (en) | Traditional Chinese medicine composition for removing acnes | |
CN103432330B (en) | Traditional Chinese medicine used for treating renal failure and preparation method thereof | |
CN103100003B (en) | Traditional Chinese medicine composition for treating acute gouty arthritis | |
CN101703738B (en) | Chinese medicament for treating gastritis and gastric ulcer | |
CN103211994B (en) | Chinese medicament for treating chronic diarrhea | |
CN105535367A (en) | Traditional Chinese medicine for treating kidney-deficiency type hypomenorrhea | |
CN104491800A (en) | Traditional Chinese medicine composition for treating chronic colitis | |
CN115137785B (en) | Membranous kidney prescription for treating idiopathic membranous nephropathy | |
CN101590208A (en) | A kind of pharmaceutical composition for the treatment of rheumatoid arthritis and preparation method thereof | |
CN103705646B (en) | A kind of Chinese medicinal enema treating ulcerative colitis | |
CN108079206A (en) | Alleviate decoction of nephrotic syndrome and preparation method thereof | |
CN102772548B (en) | A kind of preparation method for the treatment of the Chinese medicine composition of lupus erythematosus | |
CN1994415B (en) | Orally administered Chinese medicine for treating dysmenorrhea | |
CN101623493A (en) | Herba artemisiae scopariae turtle shell soup for treating liver cirrhosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |